Most Clicked SNMMI SmartBrief Stories


1. Bayer suspends radium-223 production

SNMMI SmartBrief | Oct 17, 2014

Bayer HealthCare Pharmaceuticals has halted production of prostate cancer drug radium-223, sold as Xofigo, because of problems with manufacturing. Supplies of the drug have been limited since Oct. 7, according to the FDA. Bayer said it is communicating with the FDA and providers about the issue, but it had no estimate regarding when production will resume. OncLive (10/15)


2. Technique mitigates effects of breathing during PET, data suggest

SNMMI SmartBrief | Oct 14, 2014

A study in the Journal of Physics: Conference Series demonstrates a technique for mitigating the effects of respiratory motion on PET. The approach relies on bioimpedance measurements used with electrocardiogram data to track cardiac function. The study found that when synchronizing images on the basis of bioimpedance, resolution was better and clinical parameters were affected. AuntMinnie.com (free registration) (10/13)


3. Review finds SPECT and PET useful in ischemic stroke management

SNMMI SmartBrief | Oct 16, 2014

SPECT and PET imaging could greatly improve stroke management, and a hybrid system could provide comprehensive clinical information about the condition, according to a review in the Journal of Nuclear Medicine. PET can be teamed with either CT or MR in monitoring pathophysiologic changes involved in ischemic stroke, and SPECT can be used in terms of cerebral blood volume, perfusion and hemodynamics. PET radionuclides such as C-11, O-15 and F-18 for cerebral blood volume and emerging F-18 galacto-RGD show promise in assessing angiogenesis and revascularization following stroke. MolecularImaging.net (10/15)


4. Study IDs sensitive brain areas where networks come together

SNMMI SmartBrief | Oct 15, 2014

Using data from the Iowa Neurological Patient Registry, scientists have mapped six neurological regions they call hubs, where multiple brain networks come together, and they argue that damage to such areas disrupts multiple functions. The findings could shed light on why some people experience substantial cognitive impairment following a relatively minor brain injury. The study appeared in the Proceedings of the National Academy of Sciences. Medical News Today (10/14)


5. Research traces chain of events that leads to Alzheimer's

SNMMI SmartBrief | Oct 14, 2014

A study in the journal Nature has validated the theory that amyloid deposition begins the process of Alzheimer's disease development. Stem cells were coaxed to become neurons in a petri dish. A gene linked to Alzheimer's induced amyloid and tangles with the help of an enzyme that may prove a useful target for stopping the disease. Researchers plan to use the system dubbed "Alzheimer's in a dish" for a variety of applications. New York Times (tiered subscription model), The (10/13) HealthDay News (10/13) Voice of America (10/12)


6. N.H. breast-imaging device startup obtains $6.5M

SNMMI SmartBrief | Oct 17, 2014

A regulatory filing shows that Gamma Medica has obtained $6.5 million in its latest funding round. The New Hampshire-based startup makes the LumaGEM molecular imaging system, an FDA-cleared device used as an ancillary tool to mammography in diagnosing breast cancer in women with dense breasts. MedCityNews.com (10/15)


7. "Updates on Ga-68: Outlook for the Future" webinar Thursday at 3 p.m. ET

SNMMI SmartBrief | Oct 20, 2014

Join David W. Dick, Ph.D. — October 23 at 3 p.m. ET — for a one-hour webinar focusing on current trials underway using the three Ga-68 DOTA agents (NOC/TATE/TOC), along with updates on the manufacturing, production and availability of the agents for clinical and/or investigational use. Learn more and register today. Blank (03/19)


8. Agents show promise in colorectal cancer detection

SNMMI SmartBrief | Oct 17, 2014

A study in the journal PLOS One suggests that Cellectar Biosciences' phospholipid ether analog agents CLR1502 and iodine-131 CLR1404 could provide better localization of primary and metastatic tumors in patients with colorectal cancer. Findings revealed that CLR1502 uptake in intestinal tumors distinguished malignant from nonmalignant tissues in animal models and could also detect regional lymph nodes, while iodine-131 CLR1404 was taken up by colon cancer metastases in humans and could be used in PET. AuntMinnie.com (free registration) (10/16)


9. SNMMI urges members to speak out on proposed imaging standards

SNMMI SmartBrief | Oct 14, 2014

SNMMI is calling upon its members to submit comments on the Joint Commission's Proposed Revisions to Diagnostic Imaging Services, which include disqualification of Nuclear Medicine Technology Certification Board-certified technologists from performing diagnostic CT scans. SNMMI says the proposed changes could also affect SPECT/CT and PET/CT procedures. Members have until Oct. 24 to submit comments. AuntMinnie.com (free registration) (10/13)


10. Upcoming webinar -- Updates on Ga-68: Outlook for the Future

SNMMI SmartBrief | Oct 15, 2014

Join David W. Dick, PhD -- Oct. 23 at 3 p.m. -- for a one-hour webinar focusing on current trials underway using the three Ga-68 DOTA agents (NOC/TATE/TOC), along with updates on the manufacturing, production and availability of the agents for clinical and/or investigational use. Learn more and register today. Blank (03/19)




Sign up for SNMMI SmartBrief



Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more